


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:



1. (currently amended): ~~A composition~~An aqueous composition for pharmaceutical use consisting essentially of:

a thiazole derivative of the formula (I):



wherein

R^1 is acyl;

X is a bivalent residue selected from the group consisting of  and 


and may be substituted;

Y is a bond, lower alkylene, lower alkenylene or $-CONH-$; and

Z is a group of the formula:



wherein R^2 is a group of the formula:



(wherein G is a bond, $-NHCOCH_2-$ or lower alkylene and R^4 is hydrogen, $-NH_2$ or lower alkyl);


or a pharmaceutically acceptable salt thereof,
water, and

an additive selected from the group consisting of polyol, sugar alcohol, boric acid and a salt of boric acid,

wherein the thiazole derivative, the water and the additive are present in an aqueous composition for pharmaceutical use.

2. (canceled).

3. (currently amended): The aqueous composition of claim 1, wherein R² of the formula (I) is a group of the formula:



(wherein G is a bond, -NHCOCH₂- or lower alkylene and R⁴ is hydrogen or lower alkyl);
or a pharmaceutically acceptable salt thereof.

4. (currently amended): The aqueous composition of claim 1, wherein R¹ of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

5. (currently amended): The aqueous composition of claim 1, wherein the thiazole derivative is

N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-1,3-thiazol-2-yl}acetamide,

N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,

or

N-(4-{2-[4-(2-{[amino(imino)methyl]amino}ethyl)phenyl]ethyl}-1,3-thiazol-2-yl)acetamide,

or a pharmaceutically acceptable salt thereof.

6. (currently amended): The aqueous composition of claim 1, wherein R¹ of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

7. (currently amended): The aqueous composition of claim 3, wherein R¹ of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.


8. (currently amended): The aqueous composition of Claim 1, wherein the additive is glycerin.

9. (currently amended): The aqueous composition of Claim 1, wherein the additive is mannitol.

10. (currently amended): The aqueous composition of Claim 1, wherein the additive is boric acid or a salt of boric acid.



11. (withdrawn): A method for increasing solubility of a thiazole derivative of the following formula (I) in water, consisting essentially of preparing a composition consisting essentially of:

a thiazole derivative of the formula (I):



wherein

R¹ is acyl;

X is a bivalent residue selected from the group consisting of  and 


and may be substituted;

Y is a bond, lower alkylene, lower alkenylene or -CONH-; and

Z is a group of the formula:



wherein R² is a group of the formula:




(wherein G is a bond, -NHCOCH₂- or lower alkylene and R⁴ is hydrogen, -NH₂ or lower alkyl);

or a pharmaceutically acceptable salt thereof,

water, and

an additive selected from the group consisting of polyol, sugar alcohol, boric acid and a salt of boric acid.

12. (withdrawn): The method of claim 11, wherein R² of the formula (I) is a group of the formula:



(wherein G is a bond, -NHCOCH₂- or lower alkylene and R⁴ is hydrogen or lower alkyl);

or a pharmaceutically acceptable salt thereof.

13. (withdrawn): The method of claim 11, wherein R^1 of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

14. (withdrawn): The method of claim 11, wherein the thiazole derivative is
N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,
N-{4-[2-(4-{[amino(imino)methyl]amino}phenyl)ethyl]-5-[4-(methylsulfonyl)benzyl]-
1,3-thiazol-2-yl}acetamide,
N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-5-[4-(
(methylsulfonyl)benzyl)-1,3-thiazol-2-yl]acetamide,
N-{4-[2-(4-{[hydrazino(imino)methyl]amino}phenyl)ethyl]-1,3-thiazol-2-yl}acetamide,
or
N-(4-[2-[4-(2-{[amino(imino)methyl]amino}ethyl)phenyl]ethyl]-1,3-thiazol-2-
yl)acetamide,
or a pharmaceutically acceptable salt thereof.

15. (withdrawn): The method of claim 11, wherein R^1 of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

16. (withdrawn): The method of claim 12, wherein R^1 of the formula (I) is alkylcarbonyl and X is optionally substituted by methylsulfonylbenzyl, or a pharmaceutically acceptable salt thereof.

17. (withdrawn): The method of Claim 11, wherein the additive is glycerin.

18. (withdrawn): The method of Claim 11, wherein the additive is mannitol.

19. (withdrawn): The method of Claim 11, wherein the additive is boric acid or a salt of boric acid.

20. (new): The aqueous composition of Claim 1, wherein the composition is for ocular topical administration.

21. (new): The aqueous composition of Claim 1, wherein the composition further comprises an additive selected from the group consisting of povidone and methylcellulose.